Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Cosman, Felicia, Crittenden, Daria B., Adachi, Jonathan D., Binkley, Neil, Czerwinski, Edward, Ferrari, Serge, Hofbauer, Lorenz C., Lau, Edith +9 more·2016·New England Journal of Medicine

DOI 10.1056/nejmoa1607948

Cited by (1,001)

Items 601–700 of 1,001

Bone Disease in Primary Hyperparathyroidism—Changes Occurring in Bone Metabolism and New Potential Treatment Strategies
Mirella Iwanowska, Magdalena Kochman, Alicja Szatko, Wojciech Zgliczyński, Piotr Glinicki · 2024 · International Journal of Molecular Sciences
Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab
Ian R. Reid · 2017 · BioDrugs
Preventing medication-related osteonecrosis of the jaw
Lara Zebic, Vinod Patel · 2019 · BMJ
Romosozumab in the Treatment of Osteoporosis
Alexandra O. Kobza, Αλεξάνδρα Παπαϊωάννου, Arthur N. Lau, Jonathan Derrick Adachi · 2020 · Immunotherapy
Bone union‐promoting effect of romosozumab in a rat posterolateral lumbar fusion model
Geundong Kim, Kazuhide Inage, Yasuhiro Shiga, Tomohito Mukaihata, Ikuko Tajiri, Yawara Eguchi, Miyako Suzuki, Hiromitsu Takaoka, Takashi Hozumi, Norichika Mizuki et al. · 2022 · Journal of Orthopaedic Research®
The Bone-Vascular Axis in Chronic Kidney Disease: From Pathophysiology to Treatment
Clément Vachey, Alexandre Candellier, Soline Toutain, Fabrice Mac‐Way · 2024 · Current Osteoporosis Reports
Treatment effects, adverse outcomes and cardiovascular safety of romosozumab – Existing worldwide data: A systematic review and meta-analysis
Ronald Man Yeung Wong, Pui Yan Wong, Chaoran Liu, Hei Yuet Wong, Man Ki Fong, Ning Zhang, Wing‐Hoi Cheung, Sheung Wai Law · 2024 · Journal of Orthopaedic Translation
Rheumatoid Arthritis and Osteoporosis as Prototypes of Immunosenescence in Osteoimmunology: Molecular Pathways of Inflammaging and Targeted Therapies
Ernesto Aitella, Gianluca Azzellino, Ciro Pasquale Romano, Lia Ginaldi, Massimo De Martinis · 2025 · International Journal of Molecular Sciences
Mesenchymal lineage cells and their importance in B lymphocyte niches
A. Green, V. Rudolph-Stringer, A. Chantry, Joy Y. Wu, L. Purton · 2017 · Bone
Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model
Diana Olvera, Rachel Stolzenfeld, Joan C. Marini, Michelle S. Caird, Kenneth M. Kozloff · 2018 · Journal of Bone and Mineral Research
Cortical bone adaptation to a moderate level of mechanical loading in male Sost deficient mice
Haisheng Yang, Alexander Büttner, Laia Albiol, Catherine Julien, Tobias Thiele, Christine Figge, Ina Krämer, Michaela Kneissel, Georg N. Duda, Sara Checa et al. · 2020 · Scientific Reports
Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020
SARA JANE CROMER, Kristin M. D’Silva, Elaine Wei-Yin Yu, Joan E. Landon, Rishi J. Desai, Seoyoung C. Kim · 2021 · Journal of General Internal Medicine
MicroRNAs: Emerging Regulators of Metastatic Bone Disease in Breast Cancer
Marie‐Therese Haider, Daniel J. Smit, Hanna Taipaleenmäki · 2022 · Cancers
New Insights in the Pathophysiology, Epidemiology, and Response to Treatment of Osteoporotic Vertebral Fractures
Michael Kriegbaum Skjødt, Bo Abrahamsen · 2023 · The Journal of Clinical Endocrinology & Metabolism
JAK/STAT as a Potential Therapeutic Target for Osteolytic Diseases
Mariely Araújo de Godoi, Ângelo Constantino Camilli, Karen G. A. Gonzales, Vitória Bonan Costa, Evangelos Papathanasiou, Fábio Renato Manzolli Leite, Morgana Rodrigues Guimarães · 2023 · International Journal of Molecular Sciences
A summary of the Malaysian Clinical Practice Guidelines on the management of postmenopausal osteoporosis, 2022
Terence Ing Wei Ong, Lee‐Ling Lim, Siew Pheng Chan, Winnie Siew Swee Chee, Alan Swee Hock Ch’ng, Elizabeth Gar Mit Chong, Premitha Damodaran, Fen Lee Hew, Luqman Ibrahim, Hui Min Khor et al. · 2023 · Osteoporosis and Sarcopenia
Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
Mingwei Hu, Yifan Zhang, Jianjun Guo, Cuicui Guo, Xue Yang, Xue Ma, Hao Xu, Shuai Xiang · 2023 · Frontiers in Endocrinology
Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials
Takaomi Kobayashi, Megumi Hara, Chisato Shimanoe, Tadatsugu Morimoto, Masaaki Mawatari, Koji Ito, Takafumi Shimazaki · 2024 · Journal of Bone and Mineral Metabolism
High bone mass in adults
Julien Paccou, Laëtitia Michou, S. Kolta, Françoise Debiais, Bernard Cortet, Pascal Guggenbuhl · 2018 · Joint Bone Spine
Duration-Dependent Increase of Human Bone Matrix Mineralization in Long-Term Bisphosphonate Users with Atypical Femur Fracture
Delphine Farlay, Sébastien Rizzo, Louis‐Georges Ste‐Marie, Laëtitia Michou, Suzanne N. Morin, Shijing Qiu, Pascale Chavassieux, Roland D Chapurlat, Sudhaker D. Rao, Jacques P. Brown et al. · 2020 · Journal of Bone and Mineral Research
Improved outcomes and reduced medical costs through multidisciplinary co-management protocol for geriatric proximal femur fractures: a one-year retrospective study
Yang Li, Kuan‐Kai Tung, Yi-Cheng Cho, Shih‐Yi Lin, Cheng-Hung Lee, Chih‐Hui Chen · 2022 · BMC Geriatrics
Romosozumab, clinical trials, and real-world care of patients with osteoporosis
Edward Michael Lewiecki · 2020 · Annals of Translational Medicine
Regulatory aspects of the development of drugs for metabolic bone diseases – FDA and EMA perspective
Theresa E. Kehoe, EBERHARD BLIND, Heidi Janssen · 2018 · British Journal of Clinical Pharmacology
Deciphering novel chemotherapy and its impact on dentistry
Rebecca King, Lara Zebic, Vinod Patel · 2020 · BDJ
Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
Tomohiro Shimizu, Kosuke Arita, Eihiro Murota, Shigeto Hiratsuka, Ryo Fujita, Hotaka Ishizu, Tsuyoshi Asano, Daisuke Takahashi, Masahiko Takahata, Norimasa Iwasaki · 2021 · Journal of Bone and Mineral Metabolism
Osteoanabolic therapy for osteoporosis in women
Michael R. McClung, Amanda Clark · 2021 · Climacteric
Pathogenesis and treatment of multiple myeloma bone disease
Masahiro Hiasa, Takeshi Harada, Eiji I. Tanaka, Masahiro Abe · 2021 · Japanese Dental Science Review
The role of osteoanabolic agents in the management of patients with osteoporosis
Michael R. McClung, Micol Sara Rothman, Edward Michael Lewiecki, David A. Hanley, Steven T. Harris, Paul D. Miller, David L. Kendler · 2022 · Postgraduate Medicine
Romosozumab efficacy and safety in European patients enrolled in the FRAME trial
Bente Lomholt Langdahl, Lorenz Christian Hofbauer, Serge Ferrari, Zhenxun Wang, Astrid Fahrleitner‐Pammer, Evelien Gielen, Péter Lakatos, Edward J. Czerwinski, Esteban Jódar Gimeno, Jen Timoshanko et al. · 2022 · Osteoporosis International
Position Statement: Vitamin D Intake to Prevent Osteoporosis and Fracture in Adults
Anna Han, Yongsoon Park, Young‐Kyun Lee, So Young Park, Clara Yongjoo Park · 2022 · Journal of Bone Metabolism
Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives
Sian Yik Lim, Marcy B. Bolster · 2022 · International Journal of Women s Health
Physiopathology of Osteoporosis: Nursing Involvement and Management
Sandra Valenzuela-Martínez, Marı́a Jesús Ramı́rez-Expósito, María Pilar Carrera-González, José Manuel Martı́nez-Martos · 2023 · Biomedicines
Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system
Yao Xiao, Yiqian Chen, Yan Huang, Xiao Yuan · 2023 · Scientific Reports
Osteoporosis Evaluation and Management in Spine Surgery
Steven J. Girdler, Matthew H. Lindsey, Arjun S. Sebastian, Ahmad N. Nassr · 2024 · Journal of the American Academy of Orthopaedic Surgeons
Emerging anabolic agents in the treatment of osteoporosis
Christina M. Lovato, Edward Michael Lewiecki · 2017 · Expert Opinion on Emerging Drugs
Pathophysiological characteristics and gene transcriptional profiling of bone microstructure in a low calcium diet fed laying hens
Sha Jiang, Xin Wu, M.L. Jin, X.Z. Wang, Qian� Tang, Yueting Sun, Heng Wei Cheng · 2019 · Poultry Science
The evolving role of anabolic therapy in the treatment of osteoporosis
Felicia Cosman · 2019 · Current Opinion in Rheumatology
Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis
Piet Geusens, Robert Feldman, Mary K. Oates, Thierry Thomas, Polyzois Makras, Franz Josef Jakob, Bente Lomholt Langdahl, Zhenxun Wang, Maria Rojeski, Cesar R. Libanati · 2021 · Bone
Usefulness of quantitative bone SPECT/CT for medication-related osteonecrosis of the jaw in clinical settings
Kuniyasu Moridera, Kazuhiro Kitajima, Kyohei Yoshikawa, Kazuki Takaoka, Tatsuya Tsuchitani, Kazuma Noguchi, Hiromitsu Kishimoto, Koichiro Yamakado · 2021 · Japanese Journal of Radiology
Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy
Lindsey E. Nicol, Ying Wang, Rosamund C. Smith, John H. Sloan, Sandesh C.S. Nagamani, Jay Robert Shapiro, Brendan Lee, ERIC S. ORWOLL · 2017 · Journal of Bone and Mineral Research
Laser irradiation decreases sclerostin expression in bone and osteogenic cells
Yujin Ohsugi, Sayaka Katagiri, Tomomitsu Hirota, Hiromi Niimi, Masahiro Hatasa, Kazuki Watanabe, Tsuyoshi Shimohira, Koji Mizutani, Moe Kitazawa, Ayumi Matsuzawa et al. · 2020 · The FASEB Journal
Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy
Mai Kawazoe, Kaichi Kaneko, Shotaro Masuoka, Soichi Yamada, Zento Yamada, Sei Muraoka, Karin Furukawa, Hiroshi Sato, Eri Watanabe, Keiko Koshiba et al. · 2024 · The Journal of Clinical Endocrinology & Metabolism
Exercise for Postmenopausal Bone Health – Can We Raise the Bar?
Shejil Kumar, Cassandra Smith, Roderick John Clifton-Bligh, Belinda R. Beck, Christian M. Girgis · 2025 · Current Osteoporosis Reports
Osteoporosis: Focus on Bone Remodeling and Disease Types
Chiara Castellani, Erica De Martino, Paolo Scapato · 2025 · BioChem
3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial
Benjamin Z. Leder, Sabashini K. Ramchand, Mackenzie Jordan, Savannah Ryan, Aparna Patnaik, Hang Lee, Joy N. Tsai · 2026 · The Lancet Diabetes & Endocrinology
The SFRP1 Inhibitor WAY-316606 Attenuates Osteoclastogenesis Through Dual Modulation of Canonical Wnt Signaling
Qingliang Ma, Shiyu Wang, Ziang Xie, Yang Shen, Bingjie Zheng, Chao Jiang, Putao Yuan, Congcong Yu, Liangping Li, Xiangde Zhao et al. · 2020 · Journal of Bone and Mineral Research
Real-World Management of Patients With Osteoporosis at Very High Risk of Fracture
Benjamin W. Diffenderfer, Yamei Wang, Leny Pearman, Nick Pyrih, Setareh A. Williams · 2023 · Journal of the American Academy of Orthopaedic Surgeons
An angiogenic approach to osteoanabolic therapy targeting the SHN3-SLIT3 pathway
Alisha R. Yallowitz, Jae‐Hyuck Shim, Ren Xu, Matthew Blake Greenblatt · 2023 · Bone
Executive summary: Italian guidelines for diagnosis, risk stratification, and care continuity of fragility fractures 2021
Giovanni Corrao, Annalisa Biffi, Gloria Porcu, Raffaella Ronco, Giovanni Adami, Rosaria Alvaro, Riccardo Bogini, Achille Patrizio Caputi, Luisella Cianferotti, Bruno Frediani et al. · 2023 · Frontiers in Endocrinology
Dual Inhibition of the Wnt Inhibitors DKK1 and Sclerostin Promotes Fracture Healing and Increases the Density and Strength of Uninjured Bone
Mónica Florio, Paul J. Kostenuik, Marina Stolina, Frank Asuncion, Mario S. Grisanti, Hua Zhu Ke, Michael S. Ominsky · 2023 · Journal of Bone and Joint Surgery
Sclerostin: clinical insights in muscle–bone crosstalk
Antimo Moretti, Giovanni Iolascon · 2023 · Journal of International Medical Research
Safety and efficacy of sequential treatments for postmenopausal osteoporosis: a network meta-analysis of randomised controlled trials
Yuxin Han, Yu-Yao Mo, Hui‐Xuan Wu, Junaid Iqbal, Jun‐Min Cai, Long Li, Yan‐Hong Bu, Fen Xiao, Hong‐Li Jiang, Ying Wen et al. · 2024 · EClinicalMedicine
Potassium: A Frontier in Osteoporosis
Widhilika Singh, Poonam Kushwaha · 2024 · Hormone and Metabolic Research
Reconstruction of remodeling units reveals positive effects after 2 and 12 months of romosozumab treatment
Erik Fink Eriksen, Rogely Waite Boyce, Yifei Shi, Jacques P. Brown, Donald Betah, Cesar R. Libanati, Mary K. Oates, Roland D Chapurlat, Pascale Chavassieux · 2024 · Journal of Bone and Mineral Research
Glucocorticoid-induced osteoporosis—from molecular mechanism to clinical practice
Chueh Hsuan Hsu, Chueh Lin Hsu, Ashley Langley, Caroline Wojcik, Elysee Iraganje, Bogna Grygiel‐Górniak · 2024 · Drugs & Therapy Perspectives
Interrelationships among metabolic syndrome, bone-derived cytokines, and the most common metabolic syndrome-related diseases negatively affecting bone quality
Monika Martiniaková, Vladimíra Mondočková, Veronika Kováčová, Martina Babikova, Nina Zemanová, Roman Bíro, Noémi Pénzes, Radoslav Omelka · 2024 · Diabetology & Metabolic Syndrome
The impact of a fracture liaison service with in-hospital anti-osteoporosis treatment on subsequent hip fracture and mortality rates—a single-center retrospective study
Uri Yoel, Hadar Alkobi Weiss, Adi Goldbart, E. S. Siris, David Louis Fisher, Lior Hassan, Merav Fraenkel · 2024 · Osteoporosis International
Proceedings of the 2018 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis
Edward Michael Lewiecki, John Paul Bilezikian, Lora Giangregorio, Susan L. Greenspan, Sundeep Khosla, Paul J. Kostenuik, Kelly Krohn, Michael R. McClung, Paul D. Miller, Roberto Pacifici · 2018 · Journal of Clinical Densitometry
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
Benjamin Z. Leder, Carol Zapalowski, Ming-Yi Hu, Gary Hattersley, Nancy E. Lane, Andrea J. Singer, Robin K. Dore · 2019 · Journal of Bone and Mineral Research
New Molecules Modulating Bone Metabolism – New Perspectives in the Treatment of Osteoporosis
Ivana Zofkova, Jaroslav Blahoš · 2017 · Physiological Research
Safety of Romosozumab in Osteoporotic Men and Postmenopausal Women: A Meta-Analysis and Systematic Review
Gonzalo Mariscal, Jorge H. Núñez, Sanjay Bhatia, Carlos Barrios, Pedro Domenech-Fernández · 2020 · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
Molecular Signaling Pathways and Essential Metabolic Elements in Bone Remodeling: An Implication of Therapeutic Targets for Bone Diseases
Aditi Sharma, Lalit Kumar Sharma, Rohit Goyal · 2020 · Current Drug Targets
The expression and regulation of Wnt1 in tooth movement–initiated mechanotransduction
Ei Ei Hlaing, Yoshihito Ishihara, Naoya Odagaki, Ziyi Wang, Mika Ikegame, Hiroshi Kamioka · 2020 · American Journal of Orthodontics and Dentofacial Orthopedics
Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan
Hiroshi Hagino, Katsuhiro Tanaka, Stuart L. Silverman, Michael R. McClung, SR Gandra, Mata Charokopou, K. Adachi, Ben Johnson, Björn Stollenwerk · 2021 · Osteoporosis International
Effects of vitamin D supplementation on the functional outcome in patients with osteoporotic vertebral compression fracture and vitamin D deficiency
Sangbong Ko, Chung-Mu Jun, Junho Nam · 2021 · Journal of Orthopaedic Surgery and Research
Osteoporosis: Epidemiology, Pathogenesis, Evaluation and Treatment
Manoj D. Chadha, Ram Chaddha, Hema Divakar, Hemant K Kalyan, Shobhit Seth, Poonam Shah · 2022 · Open Journal of Orthopedics
Cereblon (CRBN) deletion reverses streptozotocin induced diabetic osteoporosis in mice
Cong Yao, Xiong Guo, Wanxia Yao, Chun Zhang · 2018 · Biochemical and Biophysical Research Communications
Treatment with anti‐Sclerostin antibody to stimulate mandibular bone formation
Matthew L. Tamplen, Tristan W. Fowler, Jeffery Markey, P. Daniel Knott, Larry J. Suva, Tamara N. Alliston · 2018 · Head & Neck
Management of difficult osteoporosis
Linda Russell · 2018 · Best Practice & Research Clinical Rheumatology
Alterations in osteocyte mediated osteoclastogenesis during estrogen deficiency and under ROCK-II inhibition: An in vitro study using a novel postmenopausal multicellular niche model
Irene Simfia, Jessica Schiavi, Laoise M. McNamara · 2020 · Experimental Cell Research
The Dual Role and Therapeutic Implications of the Wnt/β-Catenin Pathway in Diabetic Kidney Disease
Yilinuer Adeerjiang, Xiao-Xue Gan, Wenting Li, Qian Li, Yiqi Jiang, Xia Shuang ZHU, Chen-Ming Hu, Panxia Wang, Sheng Jiang · 2025 · International Journal of General Medicine
The Inflammation-Energy Metabolism Axis: A Central Driver of Sarcopenia-Osteoporosis: A Narrative Review
Yifan Jiang, Xiaonan Qi, Haijian Cui, Yingtao Huang, Yibo Lv, Yu Yang, Xiaosheng Yao, Dongxiang Yang · 2026 · Calcified Tissue International
Bone Healing Around Implants in Normal and Medically Compromised Conditions: Osteoporosis and Diabetes
Dainelys Guadarrama Bello, Fabio Variola, Antonio Nanci · 2026 · Advanced Healthcare Materials
Advanced oxidation protein products aggravate age‑related bone loss by increasing sclerostin expression in osteocytes via ROS‑dependent downregulation of Sirt1
Ji‐Huan Zeng, Qiang Feng Xiao, Xiaodan Li, Jianting Chen · 2021 · International Journal of Molecular Medicine
Plumbagin is a NF-κB-inducing kinase inhibitor with dual anabolic and antiresorptive effects that prevents menopausal-related osteoporosis in mice
G. Shen, Xin Liu, Wei Lei, R. Duan, Z. Yao · 2022 · Journal of Biological Chemistry
Bone fragility: conceptual framework, therapeutic implications, and COVID-19-related issues
Giovanni Iolascon, Marco Paoletta, Sara Liguori, Francesca Gimigliano, Antimo Moretti · 2022 · Therapeutic Advances in Musculoskeletal Disease
Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis
Namki Hong, Sungjae Shin, Seunghyun Lee, Yumie Rhee · 2023 · Osteoporosis International
Sequential management of postmenopausal health and osteoporosis: An update
Joaquím Calaf, Antonio Cano, Núria Guañabens, Santiago Palacios, María Jesús Cancelo Hidalgo, Camil Castelo‐Branco, Ricardo Larrainzar‐Garijo, José Luís Neyro, Xavier Nogués, Adolfo Díez‐Pérez · 2023 · Maturitas
Real-World Effects, Safety, and Predictors of the Effectiveness of Romosozumab in Primary and Secondary Osteoporosis: An Observational Study
Kazuaki Mineta, Toshihiko Nishisho, Masahiko Okada, Mitsuhiro Kamada, Koichi Sairyo · 2024 · Bone
Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?
Athanasios D. Anastasilakis, Maria P. Yavropoulou, Andrea Palermo, Polyzois Makras, Julien Paccou, Gaia Tabacco, Anda Mihaela Naciu, Elena A. Tsourdi · 2024 · European Journal of Endocrinology
Clinical utility of anti-sclerostin antibodies
Michael R. McClung · 2017 · Bone
Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis
Edward Michael Lewiecki, John Paul Bilezikian, JOHN J. CAREY, Richard M. Dell, Catherine M. Gordon, Steven T. Harris, Michael R. McClung, Paul D. Miller, Michael Rosenblatt · 2017 · Journal of Clinical Densitometry
Bone Cell Communication Factors Provide a New Therapeutic Strategy for Osteoporosis
Jung Ha Kim, Nacksung Kim · 2020 · Chonnam Medical Journal
Notum suppresses the osteogenic differentiation of periodontal ligament stem cells through the Wnt/Beta catenin signaling pathway
Panpan Yang, Congshan Li, Yuying Kou, Yujun Jiang, Dongfang Li, Shanshan Liu, Yupu Lu, Tomoka Hasegawa, Minqi Li · 2021 · Archives of Oral Biology
Molecular Identification of Spatially Distinct Anabolic Responses to Mechanical Loading in Murine Cortical Bone
Carolyn Chlebek, Jacob A. Moore, Frederick Patrick Ross, Marjolein C. H. van der Meulen · 2020 · Journal of Bone and Mineral Research
Proceedings of the 2016 Santa Fe Bone Symposium: New Concepts in the Management of Osteoporosis and Metabolic Bone Diseases
Edward Michael Lewiecki, John Paul Bilezikian, Susan V. Bukata, Pauline M. Camacho, Bart Lyman Clarke, Michael R. McClung, Paul D. Miller, J. Shepherd · 2017 · Journal of Clinical Densitometry
Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
Michael R. McClung, Gregory C. Williams, Gary Hattersley, Lorraine A. Fitzpatrick, Yamei Wang, Paul D. Miller · 2017 · Calcified Tissue International
Risk of falls in postmenopausal women treated with romosozumab: Preliminary indices from a meta-analysis of randomized, controlled trials
Luis Möckel, Matthias Bartneck, Christina Möckel · 2020 · Osteoporosis and Sarcopenia
Denosumab withdrawal increases vertebral fracture and mortality risk compared with zoledronate
Ko‐Hsiu Lu, Shiow‐Ing Wang, Shun‐Fa Yang · 2025 · European Journal of Endocrinology
Advances in the mechanism for steroid-induced osteonecrosis of the femoral head
Runze Zhou, Yixin Bian, Xuejie Cai, Hanyang Sun, Zehui Lv, Yiming Xu, Yingjie Wang, Hao Wang, Wei Zhu, Bin Feng et al. · 2026 · Bone Research
Romosozumab and cardiovascular safety in Japan
Yasuhiro Takeuchi · 2021 · Osteoporosis and Sarcopenia
Importance of Time Point–Specific Indirect Treatment Comparisons of Osteoporosis Treatments: A Systematic Literature Review and Network Meta-Analyses
Damon Willems, M K Javaid, Rafael Pinedo‐Villanueva, Cesar R. Libanati, Alon Yehoshua, Mata Charokopou · 2022 · Clinical Therapeutics
Modeling osteoporosis to design and optimize pharmacological therapies comprising multiple drug types
Jörg, David J, Fuertinger, Doris H, Cherif, Alhaji, Bushinsky, David A, Mermelstein, Ariella, Raimann, Jochen G, Kotanko, Peter · 2022 · eLife
Efficacy and safety of pharmacologic therapies for prevention of osteoporotic vertebral fractures in postmenopausal women
Fei‐Long Wei, Quan-You Gao, Kai-Long Zhu, Heng Wei, Ming‐Rui Du, Fan Yang, Hao-Ran Gao, Tian Li, Jixian Qian, Cheng-Pei Zhou · 2022 · Heliyon
Comparison of the Clinical Efficacy of Anabolic Agents and Bisphosphonates in the Patients With Osteoporotic Vertebral Fracture: Systematic Review and Meta-analysis of Randomized Controlled Trials
Ikchan Jeon, Sung Bae Park, Bong Ju Moon, Miyoung Choi, Sung Uk Kuh, Jongtae Kim · 2024 · Neurospine
Effect of genetically predicted sclerostin on cardiovascular biomarkers, risk factors, and disease outcomes
Marta Alcalde‐Herraiz, Junqing Xie, Danielle Newby, Clara Prats, Dipender Gill, María Gordillo‐Marañón, Daniel Prieto‐Alhambra, Martí Català, Albert Prats‐Uribe · 2024 · Nature Communications
Positioning novel biologicals in CKD-mineral and bone disorders
Lida Tartaglione, Marzia Pasquali, Silverio Rotondi, Maria Luisa Muci, Adrian Constantin Covic, Sandro Mazzaferro · 2017 · Journal of Nephrology
Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments
Anastasia D. Dede, Polyzois Makras, Athanasios D. Anastasilakis · 2017 · Expert Opinion on Investigational Drugs
MLN64 deletion suppresses RANKL-induced osteoclastic differentiation and attenuates diabetic osteoporosis in streptozotocin (STZ)-induced mice
Lei Chen, Han Xueming, Duan Ruihang · 2018 · Biochemical and Biophysical Research Communications
Discovery of potential sclerostin inhibitors from plants with loop2 region of sclerostin inhibition by interacting with residues outside Pro-Asn-Ala-Ile-Gly motif
Wipawadee Yooin, Chalermpong Saenjum, Jetsada Ruangsuriya, Supat Jiranusornkul · 2019 · Journal of Biomolecular Structure and Dynamics